Pre-made Ontuxizumab benchmark antibody ( Whole mAb, anti-CD248 therapeutic antibody, Anti-CD164L1/TEM1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).
| Products Name (INN Index) | Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody |
|---|---|
| INN Name | Ontuxizumab |
| Target | CD248 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Ludwig Institute for Cancer Research,Morphotek,National Cancer Institute (USA) |
| Conditions Approved | NA |
| Conditions Active | Colorectal cancer,Malignant melanoma,Soft tissue sarcoma |
| Conditions Discontinued | Lymphoma,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD248 |
| Package |
